Related Experiment Video
Updated: May 15, 2025

Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
Amygdala neurodegeneration differentiates brain-first and body-first Parkinson's disease: An MRI study
Nils Schröter1, Laura Matinpalo1, Jonas A Hosp1
1Department of Neurology and Clinical Neuroscience, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Background:
Two distinct patterns of alpha-synuclein spread in Parkinson's disease were proposed with a body-first and a brain-first subtype. The body-first subtype originates in the periphery, while the brain-first subtype initiates in the central nervous system, notably affecting the amygdala.
Objectives:
This retrospective cross-sectional study compared the integrity of the substantia nigra and amygdala between body-first and brain-first Parkinson's disease subtypes.
Methods:
We analyzed data from 30 Parkinson's disease patients, classified into body-first (n = 21) and brain-first (n = 9) subtypes based on REM sleep behavior disorder history. Microstructural integrity was assessed using diffusion microstructure MRI.
Results:
No significant differences were found in the substantia nigra between subtypes. However, amygdala degeneration was significantly pronounced in the "brain-first" compared to the "body-first" group reflected by increased free interstitial fluid (p = 0.02, Cohen's d = -1.22).
Conclusions:
The degeneration of amygdala is distinctively pronounced in "brain-first" Parkinson's disease, supporting differential disease progression patterns between subtypes.
Related Concept Videos
Neural Regulation
Parkinson's Disease: Overview

